In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
The Real Pros and Cons of Ketamine Infusions Read More »
Can LSD and psilocybin provide relief to people suffering from difficult-to-treat conditions such as depression and anxiety? Robin Carhart-Harris is a neuroscientist and head of the Imperial Centre for Psychedelic Research, which builds on over a decade of pioneering work psychedelic research, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.
Ketamine Explained, The Next Big Antidepressant | The War on Drugs Read More »
Camilla Crisanti, Paolo Enrico, Alessio Fiorentini, Giuseppe Delvecchio, Paolo Brambilla Published 29 July 2020 | https://doi.org/10.1016/j.jad.2020.07.119 Abstract Background Most recent evidence support a rapid and sustained antidepressant effect of subanesthetic dose of intravenous ketamine in patients with major depressive disorder (MDD). However, clinical and animal studies investigating the effects of intravenous ketamine on specific functional
Can LSD and psilocybin provide relief to people suffering from difficult-to-treat conditions such as depression and anxiety? Robin Carhart-Harris is a neuroscientist and head of the Imperial Centre for Psychedelic Research, which builds on over a decade of pioneering work psychedelic research, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.
The Science of Psychedelics Read More »
A mind-altering drug called ketamine is changing the way some doctors treat depression.
Treating PTSD With Psychedelics Read More »
Adriana Feder, Sarah B. Rutter, Daniela Schiller, Dennis S.Charney Published 19 June 2020 | https://doi.org/10.1016/bs.apha.2020.05.004 Abstract A serious lack of effective pharmacotherapeutic interventions for posttraumatic stress disorder (PTSD) raises the urgent need for the development of novel treatments. Ketamine—a noncompetitive glutamate N-methyl-d-aspartate (NMDA) receptor antagonist in use for decades as an anesthetic and analgesic agent—has
The emergence of ketamine as a novel treatment for posttraumatic stress disorder Read More »
Maladaptive reward memories (MRMs) are involved in the development and maintenance of acquired overconsumption disorders, such as harmful alcohol and drug use. Here we demonstrate that the N-methyl D-aspartate (NMDA) antagonist ketamine is able to disrupt MRMs in hazardous drinkers when administered immediately after their retrieval.
Ketamine Can Reduce Harmful Drinking by “Rewriting” Your Memories Read More »
Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated ketamine administration could be a viable strategy to maintain treatment gains.
Ketamine for Unipolar and Bipolar Depression Read More »
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results.
Psychedelic Psychiatry’s Brave New World Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Ketamine to Treat Depression: A Veteran’s Story Read More »